| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Endocrine Research Unit (J.D.V.), Mayo School of Graduate Medical Education, General Clinical Research Center, Mayo Clinic, Rochester, Minnesota 55905; Endocrinology (S.M.A.), Internal Medicine, University of Virginia, Charlottesville, Virginia 22908; Endocrine Service (A.I.), Medical Section, Salem Veterans Affairs Medical Center, Salem, Virginia 24153; and Division of Endocrinology and Metabolism (C.Y.B.), Department of Internal Medicine, Tulane Medical School, New Orleans, Louisiana 70112
Address all correspondence and requests for reprints to: Johannes D. Veldhuis, Endocrine Research Unit, Mayo School of Graduate Medical Education, General Clinical Research Center, 200 First Street Southwest, Mayo Clinic, Rochester, Minnesota 55905. E-mail: veldhuis.johannes{at}mayo.edu.
The present study tests the hypothesis that a high dose of testosterone (Te) drives GH and IGF-I production, in part, by blunting autonegative feedback by the end-product peptide. To this end, we infused saline or recombinant human IGF-I (10 µg/kg·h iv for 6 h) in seven healthy men ages 5172 yr after administration of placebo (Pl) and Te in randomized order. GH release was quantitated fasting before and after injection of GHRH (1 µg/kg). Statistical analyses disclosed that Te vs. Pl: 1) increased the mean concentration of GH from 0.15 ± 0.045 to 0.48 ± 0.11 µg/liter (P = 0.007) and IGF-I from 108 ± 5.0 to 124 ± 4.1 (P = 0.047) without altering GHRH-induced GH release; 2) elevated the GH nadir from 0.13 ± 0.03 to 0.23 ± 0.06 µg/liter (P < 0.05) in the control session and from 0.06 ± 0.02 to 0.14 ± 0.04 µg/liter (P = 0.038) during IGF-I infusion; 3) augmented GHRH-stimulated GH release from 3.0 ± 0.56 (Pl) to 3.7 ± 0.52 µg/liter (Te) (P < 0.05) during IGF-I infusion; and 4) did not influence estimated IGF-I kinetics.
In summary, supplementation of a high dose of Te in middle-aged and older men attenuates IGF-I feedback-dependent inhibition of nadir and peak GH secretion. Both effects of Te differ from those reported recently for estradiol in postmenopausal women. Accordingly, we postulate that Te and estrogen modulate IGF-I negative feedback differentially.
This article has been cited by other articles:
![]() |
B. T. Velayudhan, K. E. Govoni, T. A. Hoagland, and S. A. Zinn Growth rate and changes of the somatotropic axis in beef cattle administered exogenous bovine somatotropin beginning at two hundred, two hundred fifty, and three hundred days of age J Anim Sci, November 1, 2007; 85(11): 2866 - 2872. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Muniyappa, J. D. Sorkin, J. D. Veldhuis, S. M. Harman, T. Munzer, S. Bhasin, and M. R. Blackman Long-term testosterone supplementation augments overnight growth hormone secretion in healthy older men Am J Physiol Endocrinol Metab, September 1, 2007; 293(3): E769 - E775. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Munzer, C. J. Rosen, S.M. Harman, K. M. Pabst, C. St. Clair, J. D. Sorkin, and M. R. Blackman Effects of GH and/or sex steroids on circulating IGF-I and IGFBPs in healthy, aged women and men Am J Physiol Endocrinol Metab, May 1, 2006; 290(5): E1006 - E1013. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. D. Veldhuis, J. N. Roemmich, E. J. Richmond, and C. Y. Bowers Somatotropic and Gonadotropic Axes Linkages in Infancy, Childhood, and the Puberty-Adult Transition Endocr. Rev., April 1, 2006; 27(2): 101 - 140. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |